
LOS ANGELES--Use of a radiolabeled monoclonal antibody in patients with relapsed B-cell lymphoma may allow higher doses of radiation to the tumor and less toxicity to normal organs, Oliver W. Press, MD, PhD, of the University of Washington Medical Center, Seattle, said in his ASCO presentation.